SELLAS Life Sciences Shares Rally 364% Over Year as ORR Hits 46%
SELLAS Life Sciences shares have jumped over 200% in six months and trade near a 52-week high of $5.51, buoyed by technical momentum and a 27.21% short interest. Its Phase 2 SLS009 combo trial showed a 46% overall response rate and median survival up to 8.9 months.
1. Stock Performance and Technical Momentum
Shares of SELLAS Life Sciences have surged over 200% in the past six months and are trading at $5.50, just one cent below their 52-week high of $5.51. The stock sits 31.6% above its 20-day SMA and 137.4% above its 200-day SMA, with an RSI of 72.66 and a positive MACD confirming bullish momentum.
2. Phase 2 SLS009 Trial Results
The Phase 2 study of SLS009 combined with azacitidine and venetoclax in relapsed or refractory AML-MR reported a 46% overall response rate among 35 evaluable patients, including 29% achieving complete or complete-incomplete responses. Median overall survival exceeded the 2.6-month benchmark, reaching 8.9 months in the least pretreated cohort.
3. Phase 3 REGAL Trial Update
The ongoing Phase 3 REGAL trial of Galinpepimut-S as maintenance therapy in AML after second remission has reached 72 of the 80 death events needed for final analysis. An independent monitoring committee recommended continuation without modification, anticipating completion of the final analysis before year-end.
4. Short Interest and Squeeze Potential
Short interest in SELLAS Life Sciences stands at 27.21% of float, underscoring a significant bet against the stock that could trigger a squeeze if bullish catalysts persist. High short interest combined with strong momentum may amplify volatility in coming sessions.